HLA-Haploidentical Stem Cell Transplantation for Hematologic Malignancies

Ephraim J. Fuchs, Xiao jun Huang, Jeffrey S. Miller

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Partially HLA-mismatched related, or HLA-haploidentical, donor stem cell transplantation (SCT) is a feasible therapeutic option for advanced hematologic malignancies patients who lack an HLA-matched related or unrelated donor. Advances in conditioning regimens, graft manipulation, and pharmacologic prophylaxis of graft-versus-host disease (GVHD) have reduced the risk of fatal graft failure and severe GVHD, two of the most serious complications of traversing the HLA barrier. Clinical observations reveal a potential role for natural killer (NK) cell alloreactivity in reducing the risk of relapse of acute myeloid leukemia after HLA-haploidentical SCT. NK cell infusions attempt to harness the graft-versus-leukemia effect without producing GVHD. The availability of multiple potential HLA-haploidentical related donors for most patients opens the possibility of optimizing transplantation outcome through intelligent donor selection.

Original languageEnglish (US)
Pages (from-to)S57-S63
JournalBiology of Blood and Marrow Transplantation
Issue number1
StatePublished - Jan 2010

Bibliographical note

Publisher Copyright:
© 2017


  • Adoptive immunotherapy
  • Graft-versus-host disease
  • Human leukocyte antigens
  • Natural killer cells
  • Stem cell transplantation
  • Transplantation conditioning


Dive into the research topics of 'HLA-Haploidentical Stem Cell Transplantation for Hematologic Malignancies'. Together they form a unique fingerprint.

Cite this